Advanced Therapies & Vaccines in Scotland

The global cell and gene therapy market was valued at $6.68 billion in 2019 and is expected to reach $13.23 billion in 2023 at a CAGR of 24.10% (Ref. BusinessWire). Also in 2019, a joint report from The Alliance for Regenerative Medicine (ARM) and the BioIndustry Association (BIA) stated that the UK is a leading source of innovation and development of advanced therapy medicinal products (ATMPs) in Europe. These products, which include gene therapies, cell therapies, and tissue-engineered products, are intended to augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes within the body. Scotland has a strong reputation in research & translational development in these fields and is rapidly growing a vibrant cluster of spin-out therapeutic companies, increasing clinical trials of new Advanced Therapy Medicinal Products (ATMPs) as well as expanding its manufacturing capability. 

Scotland also has established expertise in developing and manufacturing human vaccines (the global market projected to grow to $96b by 2023 according to Business Research Company) and animal vaccines (worth $9b by 2025 – Global Market Insights, Inc).

Advanced Therapies Overview

Scotland’s profile and contribution towards the growth of the UK ATMP sector is increasing rapidly. A strengthening supply chain is supporting new advanced therapy applications – fuelled by world-leading academic expertise in cell & gene therapy and regenerative medicine,. With a forward focus on translation, specialised clinical trials, and GMP manufacture and analysis, Scotland is growing a vibrant infrastructure to support end-to-end development of advanced therapies. More information is shown below

Advanced Therapies Overview
Vaccine Overview

Vaccine Overview

Human and animal vaccine development is a strength in Scotland represented by companies such as Valneva, Neogen, and GalvMed as well as the Moredun Research Institute. In addition to Valneva’s Covid-19 Vaccine programme, Scotland’s supply chain made huge contributions to the development of Covid-19 vaccines including Merck BioReliance, Charles River, Symbiosis, SGS, Ingenza & ReproCell Europe


Scotland ATMP & Vaccine Supply Chain

ATMP - Supply Chain

To view the full list of our supply chain, please visit the following link and select Therapies.

Advanced Therapies & Vaccines Growth Plan for Scotland

In response to the growth in the UKs strength in Advanced Therapies and the urgent need arising from the COVID-19 pandemic, the Life Sciences Scotland Industry Leadership Group has developed a Strategic Response Plan to outline the key actions needed to still realise the ambition of growing the Life Sciences sector in Scotland by 6% year on year, delivering a £8bn sector by 2025. The implementation of an ATMP & Vaccines Growth Plan for Scotland is an important part of this:

Over the next 3 years, Scotland will grow its capability in developing a pipeline of new ATMP/vaccine therapeutics, expand its specialist manufacturing capacity and its supporting supply chain to the extent where a strong industry, academic and clinical cluster is making a significant impact on UK and international ATMP & vaccine markets.

Translation to Clinic & Manufacturing

With strong links to the Cell & Gene Therapy Catapult, Scotland has a developing infrastructure to accelerate the translation of new therapies. Edinburgh BioQuarter is host to the University of Edinburgh’s Centre for Regenerative Medicine, has a focus for cell and gene therapy research and also home to GMP clean rooms and manufacturing capabilities of the Scottish National Blood Transfusion Service (SNBTS) and the CDMO Roslin Cell Therapies. Edinburgh BioQuarter also hosts a leading clinical site with strengths in clinical trial, imaging and data integration. This together with its role in the Advanced Therapies Treatment Centre Networks will accelerate the trial of the these Advanced Therapies (ATTC). Other sites with additional capacity for biomanufacturing include Edinburgh BioCampus and Heriot Watt Research Park (home to the Jack Copland Centre – HQ of SNBTS).

For any enquiries regarding advanced therapy medicinal products (ATMPs), please contact